Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in Castration-resistant prostate cancer

Urology

Volumn 78, Issue 4, 2011, Pages 968.e7-968.e11

  Kutikov, Alexander ^a   Makhov, Peter ^a   Golovine, Konstantin ^a   Canter, Daniel J ^a   Sirohi, Mohit ^a   Street, Ryan ^a   Simhan, Jay ^a   Uzzo, Robert G ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; PAZOPANIB; PROSTATE SPECIFIC ANTIGEN; SUNITINIB; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; MEDIATOR RELEASE; MOUSE; NICK END LABELING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 80053927147     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.07.1384     Document Type: Article

References (20)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in Metastatic Renal-Cell Carcinoma N Engl J Med 356 2007 115 124
2. H.K. Gan, B. Seruga, and J.J. Knox Sunitinib in solid tumors Expert Opin Investig Drugs 18 2009 821 834
3. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
4. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
5. C.G. Drake Immunotherapy for prostate cancer: Walk, don't run J Clin Oncol 27 2009 4035 4037
6. Y. Li, and P.J. Cozzi Angiogenesis as a strategic target for prostate cancer therapy Med Res Rev 30 2010 23 66
7. A. Cumashi, N. Tinari, and C. Rossi Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts Cancer Lett 270 2008 229 233
8. M. Dror Michaelson, M.M. Regan, and W.K. Oh Phase II study of sunitinib in men with advanced prostate cancer Ann Oncol 20 2009 913 920
9. G. Sonpavde, P.O. Periman, and D. Bernold Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2010 319 324
10. J.B. Aragon-Ching, and W.L. Dahut About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann Oncol 21 2010 183 184
11. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
12. C. Nishioka, T. Ikezoe, and J. Yang Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells Leukemia 23 2009 2304 2308
13. A. Hobisch, I.E. Eder, and T. Putz Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor Cancer Res 58 1998 4640 4645
14. T. Chen, L.H. Wang, and W.L. Farrar Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells Cancer Res 60 2000 2132 2135
15. V. Michalaki, K. Syrigos, and P. Charles Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer 90 2004 2312 2316
16. M.P. de Miguel, M. Royuela, and F.R. Bethencourt Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate Cytokines 12 2000 535 538
17. M.A. Dall'Era, S.J. Shih, J. Yang, and J. Yang Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer Prostate Cancer Prostatic Dis 4 2001 106 111
18. J.L. Perez-Gracia, C. Prior, and F. Guillén-Grima Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array Br J Cancer 101 2009 1876 1883
19. S. Limvorasak, and E.M. Posadas Pazopanib: therapeutic developments Expert Opin Pharmacother 10 2009 3091 3102
20. R.G. Uzzo, P.L. Crispen, and K. Golovine Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression Carcinogenesis 27 2006 1980 1990